ASSERTIO HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8282 USD | +5.49% |
|
+7.14% | -22.60% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the Assertio Hold...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Companyâs primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Sector
Pharmaceuticals
Calendar
2024-05-05
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8282
USD
Average target price
3
USD
Spread / Average Target
+262.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.60% | 78.78M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- ASRT Stock
- News Assertio Holdings, Inc.
- Transcript : Assertio Holdings, Inc., Q2 2023 Earnings Call, Aug 03, 2023
